Ionis Pharmaceuticals, Inc.

And welcome to the Ionis Pharmaceuticals Third Quarter 2020 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Block, Vice President, Investor Relations, to lead off the call. Please go ahead.

Thank you, Brandon. Before we begin, I encourage everyone to go to the Investor section of the Ionis website to find the press release and related financial tables available. including a reconciliation of GAAP to non-GAAP financial measures that we will discuss today. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany our discussion today. With me on today's call are Brett Monia, our Chief Executive Officer, Beth Haugen, Chief Financial Officer, Oneza Katare, our Chief Corporate Development and Commercial Officer, and Richard Geary, Executive Vice President of Development. And joining us for Q&A, we have Eric Swazier, Executive Vice President of Research, and Kyle Genet, Chief Commercial Officer of Axia. I would like to draw your attention to slide three, which contains our forward-looking language. We'll be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. And with that, I'll turn the call over to Brett.

Thanks Wade, and good morning and thank you for joining us on today's call. As we near the end of 2020, we are well positioned to achieve our next stage of growth. Since our last update, we took the very important step of acquiring Axia. We believe that together as one company, we're stronger and more efficient with an even greater ability to achieve success today and well into the future. This transaction also represents a significant step forward in the evolution and execution of our commercial strategy. By combining Axia's commercial capabilities with the Ionisone pipeline, we move closer to fully maximizing the value of these medicines. And we're very pleased with the excellent progress we're making across our Ionisone pipeline and our pipeline overall. Our five ongoing phase three studies continue to progress well. We also remain on track to begin our sixth phase three study when we initiate phase three testing of ApoC3 LRX in FCS patients later this year. We're also evaluating larger indications for this medicine with an additional pivotal study potentially starting next year. Beyond our phase three pipeline, we continue to make excellent progress with our medicines in mid-stage development. The Ionis ENAC 2.5 RX data we reported last month provided additional support for our rapidly expanding platform of inhaled antisense medicines. Lupinorsin, Ionis Factor XI LRX, and Ionis HBB-RX all advance further in development with each medicine entering Phase IIb studies. Ion 541, one of our four ALS medicines in development, entered a Phase I-II study in patients with nearly all forms of ALS regardless of family history. IONIS PKK LRX has completed enrollment in a Phase II study in patients with hereditary angioedema, which is due to read out next year and is also under evaluation in a Phase II investigator study in hospitalized patients with severe COVID-19 complications in Brazil. And we further extended the reach of our technology this past quarter through a collaboration with Genuity Science. whose unique approach for new target identification is expected to enhance our already robust drug discovery and development capabilities. With these achievements, we are closer than ever to reaching our goal of 10 or more marketing applications through 2025, which should result in a large number of new marketed products. Importantly, we remain financially strong and on track to achieve our 2020 guidance. Coming up on December 7, we will be hosting our Virtual Investor Day. During the presentation, we look forward to sharing our commercial plans, provide several development program updates, and highlight some of the great progress we're making that is extending the reach of our technology. More information about this event will be released soon. And with that, I'll hand the call over to Beth to take us through our Q3 financial results. Oneza will then talk about the Axia integration, and Richard will review our recent pipeline achievements. After Richard, I'll wrap up our prepared remarks before taking your questions. Now, over to Beth.